ライフサイエンスコーパス: vaccination strategy

1 rategy but with adjuvanted vaccine (expanded vaccination strategy).

2 ng immunomodulating molecules is a promising vaccination strategy.

3 ronment would further enhance this promising vaccination strategy.

4 Ab-deficient mice were not protected by this vaccination strategy.

5 in vaccination results and may guide future vaccination strategy.

6 ially affect the efficacy of the current HBV vaccination strategy.

7 uld be a value as a potential universal mass vaccination strategy.

8 immunity and is ideal for a prime-and-boost vaccination strategy.

9 g an Ebola virus disease outbreak via a ring vaccination strategy.

10 NYVAC (rNYVAC) vector and Env protein boost vaccination strategy.

11 novel vaccine platform for a prime-and-boost vaccination strategy.

12 velopment of improved influenza vaccines and vaccination strategies.

13 flexible context-specific dose regimens and vaccination strategies.

14 romising technological platform for improved vaccination strategies.

15 olecular adjuvants using DNA and DNA-protein vaccination strategies.

16 these antibodies are providing insights for vaccination strategies.

17 evaluate the protective potential of future vaccination strategies.

18 erlooked in the design and implementation of vaccination strategies.

19 interest in harnessing Tfh cells to improve vaccination strategies.

20 l responses, with important implications for vaccination strategies.

21 f adaptive immunity and an important goal of vaccination strategies.

22 d their potential role in improved influenza-vaccination strategies.

23 ection, and the development of novel mucosal vaccination strategies.

24 are generated will inform of ways to improve vaccination strategies.

25 e epidemiology and may inform genotyping and vaccination strategies.

26 rmining the feasibility and benefits of MenA vaccination strategies.

27 immune parameter for the evaluation of novel vaccination strategies.

28 this model to explore the impact of various vaccination strategies.

29 understanding of vaccine-induced immunity in vaccination strategies.

30 e valuable insights for future T(CD8+)-based vaccination strategies.

31 devise more effective adjunct treatment and vaccination strategies.

32 d may be employed for the design of improved vaccination strategies.

33 cell response may successfully guide subunit vaccination strategies.

34 eered CD8(+) T cells, as well as for peptide vaccination strategies.

35 disease and are important for peptide-based vaccination strategies.

36 olera transmission model to assess different vaccination strategies.

37 ortant implications for the design of future vaccination strategies.

38 ations for the development of more effective vaccination strategies.

39 ical observations, and have implications for vaccination strategies.

40 f T cell responses and a promising target in vaccination strategies.

41 potentially be modulated in support of novel vaccination strategies.

42 for the development of improved vaccines or vaccination strategies.

43 ct that could greatly affect the efficacy of vaccination strategies.

44 tribute to the formulation of more effective vaccination strategies.

45 DC lysis makes them attractive adjuvants for vaccination strategies.

46 y be considered as an important component in vaccination strategies.

47 es in direct testing of "proof of principal" vaccination strategies.

48 s uncertainty has important implications for vaccination strategies.

49 r transplantation biology, autoimmunity, and vaccination strategies.

50 (HIV) mandates the development of successful vaccination strategies.

51 improved diagnostic methods, and to seek new vaccination strategies.

52 ign of clinical trials of human vaccines and vaccination strategies.

53 sidered for the development of peptide-based vaccination strategies.

54 have important implications for prime-boost vaccination strategies.

55 d to define sites of vulnerability and guide vaccination strategies.

56 ited as adjuvants for future therapeutic and vaccination strategies.

57 alian host, in particular with regard to BCG vaccination strategies.

58 the development of different candidates and vaccination strategies.

59 us, it should be considered in future T cell-vaccination strategies.

60 should be considered for optimizing current vaccination strategies.

61 hat might benefit the rational design of new vaccination strategies.

62 children younger than 5 years of age in all vaccination strategies.

63 nfections that are highly evasive to current vaccination strategies.

64 s a priority for implementing evidence-based vaccination strategies.

65 and significantly contributes to prevention (vaccination) strategies.

66 y CTL is of increasing importance to develop vaccination strategies against a variety of established

67 e important implications for therapeutic and vaccination strategies against bacterial infection.

68 bear importance for the design of effective vaccination strategies against cancer.

69 The development of effective vaccination strategies against dengue virus (DENV) infec

70 nity.IMPORTANCE The development of effective vaccination strategies against dengue virus infection is

71 his polymorphism may be relevant for peptide vaccination strategies against HCV infection.

72 Prime-boost vaccination strategies against HIV-1 often include multi

73 ofound implications for a transition to mass vaccination strategies against human influenza, and for

74 s may have important implications for future vaccination strategies against influenza.

75 es are likely to play complementary roles in vaccination strategies against influenza: in this contex

76 Improved vaccination strategies against tuberculosis are needed,

77 d whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis.

78 t time the use of FcRs as a highly effective vaccination strategy against a highly virulent mucosal i

79 delivery of LJM11 by Listeria is a promising vaccination strategy against cutaneous leishmaniasis ind

80 This study presents a new efficient vaccination strategy against henipaviruses and opens nov

81 These results reveal a promising vaccination strategy against herpes simplex virus 2, and

82 tidylinositols (GPIs) has been proposed as a vaccination strategy against malaria.

83 We further extended our vaccination strategy against the HPAI H5N1.

84 n of M158 Moreover, our results suggest that vaccination strategies aimed at generating broad protect

85 utralizer provides the opportunity to design vaccination strategies aimed at generating similar bNAbs

86 itic cells (DDCs) is a rational approach for vaccination strategies aimed at improving humoral immune

87 +) DDCs is therefore a rational approach for vaccination strategies aimed at improving humoral respon

88 ortant implications for the design of future vaccination strategies aimed at increasing the number of

89 to other tumor antigens and are relevant for vaccination strategies aimed to induce long-term antibod

90 This vaccination strategy also induced significant tumor regr

91 ave major implications for the design of new vaccination strategies and adoptive immunotherapies.

92 d reconstitution may improve the efficacy of vaccination strategies and adoptive immunotherapy.

93 ideration of alternative maternally targeted vaccination strategies and can inform development of out

94 ults may have implications for the design of vaccination strategies and could lead to improvement of

95 Vaccination strategies and effectiveness estimates were

96 d the impact of current and potential future vaccination strategies and explored the potential trade-

97 identified from these target Ags to optimize vaccination strategies and facilitate monitoring of tumo

98 icting the spread of epidemics and designing vaccination strategies and from finding friends to uncov

99 ector cell activation, with implications for vaccination strategies and immunotherapeutic approaches.

100 mory T cells arise is important for rational vaccination strategies and improved therapeutic interven

101 Current rotavirus infant vaccination strategies and indirect protection of unvacc

102 es nontoxic PSMalpha3 derivatives for active vaccination strategies and lays the foundation for futur

103 ve the potential to have an impact on future vaccination strategies and our understanding of the role

104 se invasive disease is of concern for future vaccination strategies and should promote rigorous surve

105 We discuss different vaccination strategies and we highlight challenges facin

106 mall-world networks, to random networks, and vaccination strategy and effort interact to influence th

107 placement (cohort) and lifetime (continuous) vaccination strategies, and applied it to a Salmonella C

108 ctiveness of alternative maternally targeted vaccination strategies (antenatal delivery vs. postnatal

109 milar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollar

110 ts the need for improved surveillance before vaccination strategies are designed.

111 Influenza virus vaccination strategies are focused upon the elicitation

112 New vaccination strategies are needed to control infections

113 d full-length HAs, confirming that cHA-based vaccination strategies are superior at generating stalk-

114 No effective treatment or vaccination strategies are yet available.

115 either as monotherapy or in conjunction with vaccination strategies, are reviewed.

116 re, the potential of phosphorylcholine-based vaccination strategies as a novel tool for the preventio

117 ing peptide that may be harnessed as a novel vaccination strategy as well as a therapeutics delivery

118 Vaccination strategies based on catch-up vaccination of

119 ratory models of tuberculosis has shown that vaccination strategies based on heterologous prime-boost

120 portant considerations in the development of vaccination strategies based on live-attenuated viruses.

121 We also describe an antibacterial vaccination strategy based on immunization with the glyc

122 Here, we demonstrate that a vaccination strategy based on the stalk domain of the H3

123 This vaccination strategy, based on direct protection of thos

124 ave important implications for the design of vaccination strategies because it may be necessary to es

125 rance of infection can be achieved through a vaccination strategy, but to date, the results have been

126 In this article, we have developed a vaccination strategy by targeting protein Ags to B cells

127 These findings suggest that systemic vaccination strategies can elicit potentially important

128 t combining engineered T cells with specific vaccination strategies can improve the active tumor ther

129 This paper is based on the idea that vaccination strategies can serve as a method to identify

130 INTERPRETATION: The results show that a ring vaccination strategy can be rapidly and safely implement

131 tudy, we employed a heterologous prime-boost vaccination strategy comprising intradermally administer

132 Switching to a wP-priming vaccination strategy could reduce whooping cough inciden

133 Vaccination strategies coupling the effective, long-term

134 issue of Immunity, Chen et al. propose a new vaccination strategy, demonstrating that Th17 memory cel

135 There were many developments to improve vaccination strategies, demonstration of new molecules i

136 Vaccination strategies designed to elicit durable cellul

137 for the FVB/N mouse, but we propose that the vaccination strategy determines the dominance of epitope

138 a and its vaccine to compare Nash equilibria vaccination strategies driven by self-interest with util

139 The effectiveness of all the vaccination strategies drops off as the timing is delaye

140 The combined vaccination strategy elicited both antigen-specific T-ce

141 s lives before it was eradicated by a simple vaccination strategy: epicutaneous application of the re

142 opose that a reason that current therapeutic vaccination strategies fail to resurrect/sustain T cell

143 Conventional vaccination strategies focus on those at highest risk fo

144 These results further suggest that vaccination strategies focused on the development of cro

145 owever, numerous clinical trials are testing vaccination strategies for AD, suggesting that T and B c

146 ccinate against diseases affecting all ages, vaccination strategies for adolescents need to be review

147 and from the PCV13 era are needed to inform vaccination strategies for elderly adults.

148 t supply and little is known about effective vaccination strategies for epidemic cholera.

149 The development of autoantigen-specific vaccination strategies for Foxp3(+)Treg-induction and pr

150 rk has significant implications for improved vaccination strategies for future influenza pandemics.

151 These results suggest that novel vaccination strategies for high-risk groups, including t

152 viously used in the United Kingdom to inform vaccination strategies for influenza, with extensions to

153 Optimal hepatitis B (HBV) vaccination strategies for lung transplantation (LT) can

154 ns of augmenting the immune response both in vaccination strategies for microbial infections and in t

155 n of polio and development of more effective vaccination strategies for other pathogens.

156 these studies suggest previously unexplored vaccination strategies for pathogen-associated antigens

157 ese findings introduce previously unexplored vaccination strategies for pathogens that target the B-1

158 We also summarize infection control and vaccination strategies for patients, family members, and

159 ould prove valuable in designing therapeutic vaccination strategies for persistent viral infections.

160 However, "active" Abeta vaccination strategies for the treatment of cerebral amy

161 ate goal of designing novel patient-specific vaccination strategies for the treatment of FL.

162 and may support the development of novel DC vaccination strategies for transplantations, as well as

163 t show promise for informing therapeutic and vaccination strategies for vulnerable patients.

164 We evaluated the following adult vaccination strategies for women only and for both women

165 NA approach appears to represent a promising vaccination strategy for CHIK and other alphaviral disea

166 se results suggest the potential use of this vaccination strategy for future clinical applications.

167 alth structures to implement a screening and vaccination strategy for HCWs.

168 port further evaluation of this modified BCG vaccination strategy for HIV-exposed infants.

169 ped and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that c

170 lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.

171 of population-level immunity and the optimal vaccination strategy for long-term control of MenA menin

172 ecision makers on maternal immunization as a vaccination strategy for protection of young infants aga

173 restoration of Ag-specific tolerance through vaccination strategies, for example in type 1 diabetes p

174 cquired immunity could benefit the design of vaccination strategies, for example those aimed at elici

175 Optimization of mucosal vaccination strategies has the potential for enhancing p

176 The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcepsilonR

177 istory of Ag experience and that prime-boost vaccination strategies have important consequences on me

178 Most of the studies evaluating vaccination strategies have not taken into consideration

179 Influenza vaccination strategies have targeted elderly individuals

180 Thus, the LVS DeltacapB-rLm/iglC prime-boost vaccination strategy holds substantial promise for a vac

181 enhance antiviral immunity and promote safer vaccination strategies; however, understanding the balan

182 nclusion of multiple variants in prime-boost vaccination strategies improves recognition of variant v

183 the potential effectiveness of age-specific vaccination strategies in averting RSV incidence, we dev

184 o estimate the economic impact of a range of vaccination strategies in Burkina Faso.

185 er and warrants consideration of therapeutic vaccination strategies in combination with PD-1 blockade

186 y ultimately have an impact on the design of vaccination strategies in humans.

187 nd suggest a broad counterintuitive role for vaccination strategies in mitigating undesirable immune

188 ave important implications for the design of vaccination strategies in neoplastic or chronic infectio

189 help plan vaccination campaigns and transit vaccination strategies in Pakistan.

190 mplications for the timing of future malaria vaccination strategies in pregnant women.

191 ividuals, and has important implications for vaccination strategies in the elderly.

192 ation model to evaluate the effectiveness of vaccination strategies in the United States for fall 200

193 luated a multivalent live-attenuated mucosal vaccination strategy in a murine model of acute P. aerug

194 Here we set out to test this vaccination strategy in the ferret model.

195 d vaccines are yet available, but in a trial vaccination strategy in West Africa, recombinant, infect

196 the findings were instrumental in optimizing vaccination strategy in western Uttar Pradesh with respe

197 A universal vaccination strategy in which all individuals are given

198 then compared the impact of a mine-targeted vaccination strategy, in which miners were vaccinated wh

199 udies are needed to determine whether a ring vaccination strategy, in which vaccine is given quickly

200 erize the impact and trade-offs of potential vaccination strategies, including the introduction of in

201 New vaccination strategies incorporating NA, including PIV5-

202 In conclusion, our DC vaccination strategy induced or expanded a CMV-specific

203 ) would be improved when incorporating these vaccination strategies into the DNA priming phase, as de

204 development of prophylactic and therapeutic vaccination strategies is an important goal.

205 Developing new adjuvants and vaccination strategies is of paramount importance to suc

206 ariants for a given immunogen in prime-boost vaccination strategies is one approach that aims to impr

207 This vaccination strategy is effective at generating HA stalk

208 Our in situ vaccination strategy is feasible also in MF and the clin

209 A seasonal vaccination strategy is likely to provide the most direc

210 -29 years of age, the most effective modeled vaccination strategy is to conduct mass vaccination camp

211 For safety reasons, human vaccination strategies largely use attenuated nonreplica

212 These data suggest that mucosal pneumococcal vaccination strategies may be important for vulnerable p

213 V-A16 and EV-A71 and we explore what spatial vaccination strategies may best reduce the burden of HFM

214 et of epidemic, during which the outcomes of vaccination strategies may differ significantly and are

215 DC1 vaccination strategies may therefore have potential for

216 This vaccination strategy might be developed as a neoadjuvant

217 erd effects might render a year-round infant vaccination strategy more appealing, although it is curr

218 otal number of memory cells, indicating that vaccination strategies need to consider this issue.

219 In a targeted test of five vaccination strategies on a small-world network (probabi

220 Our findings shift the focus of pandemic vaccination strategies onto younger populations and illu

221 PLs could improve the therapeutic outcome of vaccination strategies or can be used for ex vivo enrich

222 ense burden of tuberculosis, new vaccines or vaccination strategies, or both, are urgently needed.

223 An analysis of vaccination strategies over time highlights the transiti

224 demonstrate for the first time that an oral vaccination strategy prevents Pneumocystis infection.

225 We show that prime-boost vaccination strategies provide protection against both l

226 The combined vaccination strategy resulted in increased antigen-speci

227 These results suggest that vaccination strategies should attempt to provide sustain

228 Universal influenza vaccination strategies should be capable of protecting a

229 Novel anti-HCV vaccination strategies should target the induction of TL

230 Under the best assumptions, optimal vaccination strategies substantially reduced the illness

231 will allow for an exploration of alternative vaccination strategies such as different age-spacings, f

232 New vaccination strategies, such as increased vaccine dose,

233 not as efficient as many other potential HPV vaccination strategies, such as increasing primary 9vHPV

234 the development of antimicrobial therapies, vaccination strategies, targeted public health measures,

235 o, and imply that more effective therapeutic vaccination strategies targeting CD8+ Tcm in patients on

236 rstanding initiation of immune responses and vaccination strategies targeting DCs and activated monoc

237 mpartmentalization is valuable for designing vaccination strategies targeting distal mucosae.

238 This finding has implications for vaccination strategies targeting T(CD8) responses to can

239 These results suggest that vaccination strategies targeting the ICOS and Bcl6 pathw

240 enicity of rSeV-based vaccines, but all four vaccination strategies tested resulted in complete prote

241 In this article, we describe a novel vaccination strategy, tested preclinically in mice, for

242 they recognize the virus, and we discuss new vaccination strategies that aim to mimic natural evoluti

243 rates and evaluate the outcomes of different vaccination strategies that are influenced by the level

244 oal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent

245 e way for the development of next-generation vaccination strategies that completely prevent malaria.

246 tant implications for the design of maternal vaccination strategies that could synergize with ART dur

247 elopment of recombinant and vectored subunit vaccination strategies that have, however, not yet match

248 Influenza A(H5N1) vaccination strategies that improve the speed of the imm

249 exploration of the MV1-F4 vector modality in vaccination strategies that may limit HIV-1 infectivity.

250 y of ADCC as a viable approach for targeting vaccination strategies that promote FcgammaRI/III scaven

251 T-2 adapters, our results suggest that human vaccination strategies that specifically facilitate SLAM

252 ugh the peripheral tissues and highlight new vaccination strategies that take advantage of this newly

253 ysis of a PCV trial can assist in developing vaccination strategies that target specific geographic s

254 on of YF-17D, and highlight the potential of vaccination strategies that use combinations of differen

255 up the possibility for microneedle-based HIV vaccination strategies that, once fully developed, will

256 We have used a vaccination strategy that combines synthetic peptides re

257 ay allow the development of an efficient HIV vaccination strategy that is capable of inducing both ro

258 cles, or dense bodies, may constitute a safe vaccination strategy that mimics natural infection.

259 tive, wildlife epidemiologists could adopt a vaccination strategy that protects a population from the

260 th an urgent need for new and more efficient vaccination strategies, the integration of these data wi

261 me are critical to allow the optimization of vaccination strategies to effectively stimulate immune r

262 Within this context, we discuss vaccination strategies to elicit broad and potent immune

263 ble public health interest in developing new vaccination strategies to improve control of pertussis.

264 Better vaccination strategies to improve response rate are need

265 f countries to implement maternally targeted vaccination strategies to protect vulnerable infants, bu

266 The optimal long-term vaccination strategies to provide population-level prote

267 ces and will help policy makers to formulate vaccination strategies to reduce the burden of severely

268 DCs present a promising cellular target for vaccination strategies to resolve chronic liver infectio

269 In this study, we used an aerosol vaccination strategy to administer AERAS-402, a replicat

270 ous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses t

271 of NY-ESO-1 to APC appears to be a promising vaccination strategy to efficiently generate integrated

272 ion peptide, it may be possible to develop a vaccination strategy to induce these CD4(+) T cells, whi

273 New vaccination strategies under investigation include vacci

274 xtremely useful for modeling the efficacy of vaccination strategies under the real-world conditions o

275 odel, we searched for cost-effective booster vaccination strategies using a genetic algorithm.

276 We have employed a novel vaccination strategy using a secreted protein, chlamydia

277 A prime-boost intranasal vaccination strategy using TBI in the context of a bcmd-

278 ims to compare the impact of alternative HPV vaccination strategies, using data from Sweden, a high-i

279 The qHPV vaccination strategy was cost saving; it decreased lifet

280 Our data shows that a prime-boost vaccination strategy was effective in eradicating 3LL lu

281 The future disease burden for each vaccination strategy was predicted using a dynamic trans

282 d Gram-positive bacteria-dendritic cell (DC) vaccination strategy, we determined that in vivo depleti

283 All vaccination strategies were found to be preferable to a

284 The cost-effectiveness ratios for vaccination strategies were more favorable if the benefi

285 Using a total of 28 baboons, different vaccination strategies were used including recombinant S

286 both encoding mouse STEAP (mSTEAP) and three vaccination strategies were used.

287 ated with live P. murina using a prime-boost vaccination strategy were protected from a subsequent lu

288 n together, our findings provide a potential vaccination strategy where heterologous influenza immuni

289 g the first 10 years after the start of each vaccination strategy, whereas the existing program yield

290 Second, I describe a passive vaccination strategy whereby recombinant adeno-associate

291 Here, we describe a peptide vaccination strategy, which is highly effective in delay

292 e modified vaccinia virus Ankara (MVA)-boost vaccination strategy, which uses mismatched Gag immunoge

293 Improved vaccination strategies will be needed to drive persisten

294 Our findings suggest that different vaccination strategies will be required to optimize prot

295 Using more effective vaccines and vaccination strategies will increase population immunity

296 inform policy recommendations for long-term vaccination strategies with MenAfriVac.

297 Regional-specific influenza vaccination strategies would be optimal in China; in par

298 parameters into uncertainty in which of two vaccination strategies would provide a better response t

299 A convenient but more immunogenic vaccination strategy would enhance vaccine performance,

300 e vaccine supply, this alternative influenza vaccination strategy would help control interpandemic in